Hi All, this is probably a silly question but Ph1 trials are primarily about safety and ascertaining optimal dosage levels; without wanting to ignore any efficacy findings - Is it at all possible that if safety protocols are satisfactorily passed can future Ph.2 trials use cohorts that haven’t had their immune systems compromised by chemotherapy or other current SOC?
Hi All, this is probably a silly question but Ph1 trials are...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $230.8K | 4.757M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 6987667 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2337559 | 20 |
View Market Depth
| Last trade - 15.35pm 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |